Emerald Advisers, LLC Mirati Therapeutics, Inc. Transaction History

Emerald Advisers, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Oct 28, 2021	SELL	$132.13 - $177.45 $39,639 - $53,235	-300 Closed	0 $0
Q2 2021 Jul 29, 2021	SELL	$144.0 - $179.73 $3.72 Million - $4.64 Million	-25,810 Reduced 98.85%	300 $48,000
Q1 2021 Apr 29, 2021	SELL	$158.92 - $221.61 $12.1 Million - $16.8 Million	-75,936 Reduced 74.41%	26,110 $4.47 Million
Q4 2020 Jan 29, 2021	SELL	$162.05 - $240.27 $12.8 Million - $19 Million	-78,991 Reduced 43.63%	102,046 $22.4 Million
Q3 2020 Oct 28, 2020	SELL	$113.26 - $167.27 $929,411 - $1.37 Million	-8,206 Reduced 4.34%	181,037 $30.1 Million
Q2 2020 Jul 28, 2020	SELL	$72.01 - $120.39 $2.71 Million - $4.53 Million	-37,656 Reduced 16.6%	189,243 $21.6 Million
Q1 2020 Apr 30, 2020	BUY	$69.78 - $116.21 $2.16 Million - $3.6 Million	30,959 Added 15.8%	226,899 $17.4 Million
Q4 2019 Jan 29, 2020	BUY	$70.76 - $128.86 $4.41 Million - $8.03 Million	62,330 Added 46.65%	195,940 $25.2 Million
Q3 2019 Oct 31, 2019	BUY	$77.91 - $109.6 $10.4 Million - $14.6 Million	133,610 New	133,610 $10.4 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Emerald Advisers, LLC, based on Form 13F filings with the SEC.

Stay updated on Emerald Advisers, LLC with notifications on news.